Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP

Muratcan Menteş1, Başak Buse Karakuzulu1, Gönlüm Bahar Uçar1

  • 1Izmir University of Economics, Faculty of Engineering, Department of Genetics and Bioengineering, 35330 Balçova, İzmir, Turkey.

Insights

This study investigates PI3K inhibitors targeting PIK3CA mutations in cancer. Alpelisib shows consistent binding, while inavolisib binds strongly to wild-type and H1047R mutants, but E542K impairs binding for inavolisib and serabelisib.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The PI3K pathway is crucial in cancer, with PIK3CA being frequently mutated.
  • Development of PI3K inhibitors like alpelisib offers cancer treatment potential.
  • The precise interactions of inhibitors with mutated PI3Kα remain unclear.

Purpose of the Study:

  • To elucidate the binding interactions and affinities of PI3Kα inhibitors with PIK3CA hotspot mutations.
  • To understand the impact of mutations on inhibitor efficacy and natural ligand binding.
  • To guide personalized medicine strategies for PIK3CA-mutated cancers.

Main Methods:

  • Molecular dynamics (MD) simulations to analyze protein-ligand interactions.
  • Principal component analysis (PCA) to study protein complex motions.
  • Molecular mechanics with the Poisson-Boltzmann surface area (MM-PBSA) for binding affinity calculations.

Main Results:

  • Alpelisib demonstrated consistent binding across all tested PIK3CA mutations.
  • Inavolisib exhibited higher binding affinity for wild-type and H1047R PI3Kα.
  • The E542K mutation significantly reduced inavolisib and serabelisib binding.
  • Mutations decreased the binding affinity of the natural ligand ATP to PI3Kα.

Conclusions:

  • Inhibitor efficacy varies significantly with specific PIK3CA mutations.
  • PIK3CA mutations may alter the oncogenic mechanism by affecting ATP binding.
  • These findings support the development of mutation-specific PI3K inhibitors for personalized cancer therapy.